Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Nektar Therapeutics

Nektar Therapeutics (NASDAQ: NKTR) insider transactions

In the twelve months to 10 November 2026, executives and directors of Nektar Therapeutics reported 16 open-market sales of 40,930 shares ($2.4m) and 0 open-market purchases, by 3 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Nektar Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
23 September 2026Ajer Jeffrey RobertDirectorGrant or award+2,000—4,277Form 4
23 September 2026Brainard DianaDirectorGrant or award+2,000—3,904Form 4
23 September 2026Chess RobertDirectorGrant or award+2,000—19,019Form 4
23 September 2026Greer R ScottDirectorGrant or award+2,000—22,239Form 4
23 September 2026Whitfield Roy ADirectorGrant or award+2,000—16,417Form 4
18 August 2026Robin Howard WPresident & CEOOpen-market sale−418$71.9854,627Form 4
18 August 2026Zalevsky JonathanChief R&D OfficerOpen-market sale−186$71.989,570Form 4
30 June 2026Zalevsky JonathanChief R&D OfficerOpen-market sale−5,681$70.009,756Form 4
17 June 2026Robin Howard WPresident & CEOOpen-market sale−5,500$60.8159,545Form 4
17 June 2026Robin Howard WPresident & CEOOpen-market sale−4,500$61.6555,045Form 4
16 June 2026Robin Howard WPresident & CEOOpen-market sale−5,303$59.9769,742Form 4
16 June 2026Robin Howard WPresident & CEOOpen-market sale−4,697$60.7165,045Form 4
15 June 2026Zalevsky JonathanChief R&D OfficerOpen-market sale−5,538$60.7115,437Form 4
19 May 2026Robin Howard WPresident & CEOOpen-market sale−444$65.5175,045Form 4
19 May 2026Zalevsky JonathanChief R&D OfficerOpen-market sale−199$65.5120,975Form 4
18 February 2026Robin Howard WPresident & CEOOpen-market sale−423$73.0075,489Form 4
18 February 2026Zalevsky JonathanChief R&D OfficerOpen-market sale−180$73.0021,174Form 4
20 January 2026Zalevsky JonathanChief R&D OfficerOpen-market sale−3,867$35.6721,354Form 4
22 December 2025Robin Howard WPresident & CEOGrant or award+21,667—75,912Form 4
22 December 2025Zalevsky JonathanChief R&D OfficerGrant or award+6,250—25,221Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Nektar Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.